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Abstract
Background: Prohibitin (PHB), a pleiotropic protein overexpressed in several tumor types, has been implicated in
the regulation of cell proliferation, invasive migration and survival. However, PHB expression and its biological
function in gallbladder cancer (GBC) remain largely unknown.
Methods: PHB and p-ERK protein expressions were determined in human GBC tissues by immunohistochemistry
(IHC). The effects of PHB knockdown on GBC cell proliferation and invasiveness were evaluated using Cell Counting
Kit-8 (CCK-8) cell viability, cell cycle analysis, transwell invasion and gelatin zymography assays. Subcutaneous
xenograft and tail vein-lung metastasis tumor models in nude mice were employed to further substantiate the role
of PHB in GBC progression.
Results: PHB protein was overexpressed in GBC tissues and was significantly associated with histological grade,
tumor stage and perineural invasion. Furthermore, PHB expression was negatively associated with overall survival in
GBC patients. In vitro experimental studies demonstrated that the downregulation of PHB expression by lentivirus-
mediated shRNA interference not only inhibited the ERK pathway activation but also reduced the proliferative and
invasive capacities of GBC cells.
Moreover, PD0325901, a specific inhibitor of MEK, markedly impaired PHB- mediated phosphorylation of ERK
protein. IHC statistical analyses further validated that PHB expression was positively correlated with ERK protein
phosphorylation levels in GBC tissue samples. In vivo, PHB depletion also resulted in dramatic reductions in the
growth and metastasis of GBC cells.
Conclusion: Our findings demonstrate that PHB overexpression predicts poor survival in GBC patients. PHB could
serve as a novel prognostic biomarker and a potential therapeutic target for GBCs.
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Background
Gallbladder cancer (GBC) represents the most com-
mon malignancy of the biliary tract with a poor prog-
nosis. The median survival time is less than one year,
and the 5-year overall survival rate is approximately
5 % [1, 2]. Currently, radical resection at an early stage
is considered to be potentially curative therapy for
GBCs. However, due to the lack of typical symptoms
and specific biomarkers, most patients are identified at
advanced stages and miss the chance for curative re-
section. Moreover, palliative chemotherapy and radi-
ation therapy only offer limited benefits to advanced
GBCs [3, 4]. Therefore, it is desirable to explore the
molecular mechanisms involved in GBC progression
and to develop effective therapeutic strategies for prog-
nosis improvement.
Mutational activation of the Ras-raf-MEK-ERK sig-
naling pathway is frequently observed in human can-
cers, including GBC, and plays a prominent role in the
regulation of malignant cellular proliferation, migra-
tion, invasion and survival [5–8]. These observations
have promoted the development of new molecularly
targeted therapies, such as Raf and MEK kinase inhibi-
tors. Unfortunately, cancer cells quickly adapt to these
new targeted agents, and tumors with acquired resist-
ance can emerge within several months following the
primary treatments [9–11]. Alternatively, therapeutics
targeting regions outside the kinase domain might pro-
vide a new paradigm in Ras-raf-MEK-ERK pathway-
targeted therapy [12, 13]. Recent studies have demon-
strated that prohibitin (PHB), an evolutionarily conserved
and ubiquitously expressed protein, is required for the
membrane localization and activation of C-Raf by the
oncogene Ras [14]. Interestingly, our microarray analysis
of differential gene expression has also revealed that
PHB expression is substantially upregulated in GBCs
compared with that in their adjacent normal gallbladder
tissues (unpublished data). This finding prompted our
interest in investigating PHB expression and its bio-
logical function in GBCs and led us to explore whether
PHB could serve as a potential therapeutic target in
GBC patients.
In the present study, we determined PHB protein
expression in GBC tissue samples using immunohisto-
chemistry (IHC) staining and subsequently analyzed
its clinicopathologic significance. We also investigated
the role of PHB in regulating cell proliferation and in-
vasion through the extracellular signal-regulated kinase
(ERK) pathway in K-ras mutant and wild-type GBC
cells. Our findings suggest that PHB overexpression
predicts poor prognosis in GBC patients and, more
importantly, that PHB could potentially serve as a
novel therapeutic target in the oncogenic Ras-driven
GBCs.
Methods
Study population, GBC cell lines and chemicals
This study was reviewed and approved by the ethics
committee of Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University. Written informed con-
sent was obtained from all of the patients enrolled in
this study. GBC tissue specimens were obtained from
74 patients who underwent radical cholecystectomy
(without prior radiotherapy or chemotherapy) from 2004
to 2012 in the Department of General Surgery, Xinhua
Hospital. Additionally, 60 patients with chronic chole-
cystitis who underwent simple cholecystectomy were
included as controls. The tumor stage for the GBC
participants was defined according to the 7th AJCC-
TNM classification system. The present GBC study
population included 21 males and 53 females with a
mean age of 66 years (range 39–86 years). All patients
were periodically followed up for survival data until
July 2014. The human GBC cell lines NOZ (K-ras mu-
tant) and SGC-996 (K-ras wild-type) were obtained
from the Cell Bank of the Chinese Academy of Sci-
ences (Shanghai, China) [5]. The NOZ cells were cul-
tured in William’s medium E (Lonza, Belgium, WI),
and the SGC-996 cells were maintained in RPMI
1640 medium (Gibco, Gaithersburg, MD) at 37°C in a
humidified 5 % CO2 incubator. Both media were
supplemented with 10 % fetal bovine serum (FBS).
PD0325901 was obtained from Selleckchem (Houston,
TX, USA).
Quantitative immunohistochemistry assays
IHC staining was performed to investigate PHB, phos-
phorylated ERK (p-ERK), matrix metalloproteinase 9
(MMP-9) and proliferating cell nuclear antigen (PCNA)
expression in the formalin-fixed and paraffin-embedded
GBC tissues using a standard immunoperoxidase stain-
ing procedure. The primary antibodies used were PHB
(Abcam, cat # ab1836), p-ERK (Cell Signaling, cat #
4370), MMP-9 (Santa Cruz Biotechnology, cat # sc-
21733) and PCNA (Abcam, cat # ab19166). A semi-
quantitative scoring system was employed to evaluate
the protein expression based on the staining intensity
and percentage of stained cells. Immunostaining inten-
sity (i) was classified as lack of staining (0), mild stain-
ing (1), moderate staining (2) and strong staining (3).
The percentage of stained cells (ii) was divided into five
grades: ≤5 % (0), 6–25 % (1), 26–50 % (2), 51–75 % (3)
and ≥75 % (4). The score for each section was calcu-
lated as (i) × (ii), and the result was then defined as
negative (0), weakly positive (1–3), moderately positive
(4–7) and strongly positive (8–12). A score of 0–3 was
categorized as PHB/p-ERK-negative, and a score of 4–
12 was classified as PHB/p-ERK-positive.
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Immunofluorescence and western blotting analysis
Immunofluorescence staining was employed to investigate
PHB protein expression in NOZ and SGC-996 cells. After
the fixation and permeabilization, the cells were probed
with the primary antibodies against PHB (Abcam, cat #
ab1836) and were then incubated with Cy3 rabbit anti-
mouse IgG. The cells were counterstained with DAPI and
then imaged under a fluorescence microscope. For west-
ern blotting analysis, equal amounts of protein were sepa-
rated by SDS-polyacrylamide gel electrophoresis. The
proteins were then blotted onto a PVDF membrane and
probed with the primary antibodies against PHB (Abcam,
cat # ab1836), p-ERK (Cell Signaling, cat # 4370), ERK
(Cell Signaling, cat # 4695), MMP-9 (Santa Cruz Biotech-
nology, cat # sc-21733) or β-actin (Sigma-Aldrich, cat #
AC-15). Afterwards, the blots were incubated with HRP-
conjugated secondary antibodies, followed by enhanced
chemiluminescence (ECL) detection.
RNA interference, construction of plasmids and transfection
For pFH1UGW lentivirus-mediated silencing of PHB, the
short hairpin RNA (shRNA) sequence that effectively
targeted human PHB was 5′-CAGAAAUCACUGUGAAA
UUTT-3′. Recombinant lentiviruses expressing PHB shRNA
or negative control shRNA (sh-PHB or sh-NC) were pro-
duced by Genechem (Shanghai, China). The NOZ and
SGC-996 cells were infected with concentrated virus ac-
cording to the manufacturer’s instructions. The plasmids
pCDNA3.1-Prohibitin was made by inserting human pro-
hibitin cDNA into a pCDNA3.1 expression vector. Empty
vector-transfected cells (MOCK) were used as control.
Constructs were transfected into cells using Lipofectamine
2000. The PHB expression in the infected cells was vali-
dated by western blotting assay.
In vitro cell proliferation assay
Cell viability was analyzed using the Cell Counting Kit-8
(CCK-8) assay according to the manufacturer’s instruc-
tions (Dojindo Laboratories, Kumamoto, Japan). The ab-
sorbance values of NOZ and SGC-996 cells at various
time points after transfection were measured using a mi-
croplate reader. Moreover, DNA synthesis was determined
by the percentage of cells showing 5-ethynyl-2’-deoxyuri-
dine (Edu) incorporation into DNA. Briefly, the trans-
fected cells were cultured with 10 μM Edu and then fixed
in 4 % paraformaldehyde. After the permeabilization, the
cells were reacted with 1× Apollo reaction cocktail (Ribo-
Bio, Guangzhou, China). The cells nuclei were coun-
terstained with Hoechst 33342 and visualized under a
fluorescence microscope.
Flow cytometric cell cycle and cell apoptosis analysis
The effect of PHB depletion on cell cycle progression
was determined by flow cytometry. After fixation, the
transfected cells were stained with propidium iodide (PI)
solution (50 μg/ml PI and 100 μg/ml RNase A in PBS)
and then subjected to cell cycle analysis. The extent of
cell apoptosis was measured using Annexin V/PI double
staining. Briefly, 100 μl of binding buffer containing 2.5
μl of Annexin V-FITC and 1μl of PI was added to the
transfected cell suspension, which was then incubated
for 30 min in the dark. The samples were analyzed with
a FACScan flow cytometer.
In vitro cell migration and invasion assay
For the wound-healing migration assay, the transfected
NOZ and SGC-996 cells were seeded into 6-well plates
and grown to confluence. Wounds were created by scrap-
ing confluent cell monolayers with a 1ml pipette tip. Pho-
tomicrographs were taken at time points 0 and 24 h after
wounding. The percentage (%) change in migration was
determined via comparison of the differences in wound
width. Moreover, the effects of PHB knockdown on cell
migration and invasion were evaluated using 8-μm trans-
well filters (BD Biosciences, Franklin Lakes, NJ). Briefly,
the transfected NOZ and SGC-996 cells were suspended
in 0.5 ml serum-free media and added into the upper
chamber with an uncoated or Matrigel-coated membrane,
whereas medium containing 10 % FBS was added to the
lower chamber. After incubation for 24 h, the cells that
migrated or invaded through and adhered to the bottom
of the membrane were fixed and stained. Five random
fields (100× magnification) were captured for each mem-
brane, and the migratory and invasive cells were counted
and averaged.
Gelatin zymography
The conditioned media of the transfected NOZ and SGC-
996 cells were collected and concentrated with centrifugal
filters. A gelatin zymography assay was conducted to
evaluate the influence of PHB depletion on the active
MMP secretion as previously described [15]. Briefly, equal
amounts of protein were separated using 10 % SDS-PAGE
co-polymerized with 0.1 % gelatin as a substrate (Invitro-
gen, CA). After electrophoresis, the gels were renatured
for 1 h at room temperature in 1 × zymogram renaturing
buffer (Invitrogen, CA) and incubated at 37°C overnight
in 1 × zymogram developing buffer (Invitrogen, CA). The
gels were stained with Coomassie brilliant blue and de-
stained with 20 % methanol and 10 % acetic acid in
distilled water until clear bands could be visualized. The
activities of the MMP bands were quantified using
densitometry.
In vivo subcutaneous xenograft, peritoneal invasion and
tail vein-lung metastasis tumor models
The use of animals and the experimental protocol
were approved by the Institutional Animal Care and
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Use Committee of Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University. All experiments were per-
formed in accordance with relevant guidelines and
regulations for the welfare and use of animals in can-
cer research.
BAL B/C nude mice were randomly divided into the
Lv-sh NC group and the Lv-sh PHB group. Subcutane-
ous xenograft, peritoneal invasion and tail vein-lung me-
tastasis tumor models were established as previously
described [16–18]. For the subcutaneous xenograft assay,
tumor growth was monitored every 4 days. On day 28,
the tumor tissues were harvested for further IHC stain-
ing and terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) apoptosis analysis. For the
peritoneal invasion assay, on day 28 after the tumor in-
oculation, the peritoneal invasion rate was calculated
based on the invasive tumors that appeared on the peri-
toneal cavity. In the tail vein-lung metastasis assay, the
lung metastasis rate was quantified based on the meta-
static foci that appeared on the lungs.
TUNEL apoptosis assay
The extent of cell apoptosis in the tumor specimens from
the subcutaneous xenograft models was evaluated using a
TUNEL apoptosis assay according to the manufacturer’s
instructions (Roche, Basel, Switzerland). For quantitative
analysis, the TUNEL-positive cells that fulfilled the mor-
phological criteria of apoptosis were counted in 5 ran-
domly chosen fields (400 ×magnification). The results are
expressed as the mean percentage of apoptosis cells.
Statistical analysis
All statistical analyses were performed using SPSS 18.0
software (SPSS Inc., Chicago, IL). The data are expressed
as the mean ± standard deviation (SD). Statistical signifi-
cance for the measurement data was determined using
an independent Student’s t-test. The categorical variables
were analyzed employing a Pearson’s chi-square test.
The Kaplan-Meier test was performed for univariate sur-
vival analysis. Multivariate analysis was determined using
the Cox proportional hazards model. Treatment differ-
ences with a two-sided p value < 0.05 were considered
significantly different.
Results
PHB expression was upregulated and associated with
adverse clinical outcomes in GBC patients
To determine the role of PHB in GBC progression, PHB
protein expression was measured in 74 GBC and 60
cholecystitis tissue specimens using IHC staining. As
shown in Fig. 1a, PHB was predominantly expressed in
the plasma membrane and cytoplasm of both GBC and
normal gallbladder epithelial cells. Based on the IHC
staining scoring, PHB protein was strongly expressed in
47.3 % (35/74), moderately expressed in 29.7 % (22/74)
and weakly expressed in 23 % (17/74) of the GBC sam-
ples. In contrast, 65 % (39/60) of the cholecystitis tissues
exhibited PHB-weak expression, and PHB-moderate ex-
pression was only detected in 35 % (21/60) of the chole-
cystitis specimens (Fig. 1b).
Next, we evaluated the correlation between PHB expres-
sion and clinicopathologic parameters in GBC patients.
As shown in Table 1, PHB expression was significantly as-
sociated with histologic grade, tumor stage and perineural
invasion, whereas no significant differences were identified
in PHB expression with respect to patient age, gender and
lymph node metastasis. More intriguingly, the Kaplan-
Meier analysis demonstrated that PHB expression was
negatively associated with overall survival in GBC patients
(Fig. 1c). The median survival time for the PHB-negative
subset was 18.5 months. In contrast, the median survival
time in the PHB-positive subset was dramatically reduced
to 9 months. Moreover, multivariate Cox regression ana-
lysis confirmed that PHB might be an independent prog-
nostic factor in GBC patients (Fig. 1d).
PHB was involved in the modulation of the ERK pathway
in GBC
Recent studies in human cervical cancer have revealed
that PHB could serve as a scaffold protein required for the
Ras-mediated Raf membrane localization and activation
[14]. Here, we explored the potential involvement of PHB
in the Ras-Raf-MEK-ERK signaling cascades in GBC. As
shown in Fig. 2a, PHB was primarily localized in the mem-
brane and cytoplasm of human GBC cell lines (NOZ and
SGC-996). Of note, the PHB expression level in NOZ cells
harboring the K-ras mutation was much higher than that
in SGC-996 cells (K-ras wild-type). Moreover, PHB ex-
pression was concordantly associated with the proportion
of p-ERK among total ERK protein (Fig. 2b). Meanwhile,
we also analyzed the correlation between PHB expression
and p-ERK protein levels using duplicate sections of 74
GBC specimens and found that PHB expression was posi-
tively associated with p-ERK protein levels (Fig. 2c). In
vitro, PHB depletion resulted in a dramatic reduction in
ERK pathway activation, as determined by the decreased
p-ERK levels (Fig. 2d). Furthermore, PD0325901, a specific
inhibitor of MEK, markedly impaired PHB- mediated
phosphorylation of ERK protein and also partially abro-
gated the stimulatory effects of PHB overexpression on
GBC cells’ invasiveness (Fig. 2e and f). Collectively, these
findings illustrate that PHB might be critically involved in
ERK pathway activation in GBC.
Downregulation of PHB expression inhibited GBC cell
proliferation in vitro
The findings presented above revealed the prognostic
value of PHB and its regulatory role in the ERK pathway
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in GBCs. Next, we investigated the effects of PHB deple-
tion on GBC cell proliferation using CCK-8 cell viability,
Edu DNA synthesis analysis and flow cytometry assays.
As shown in Fig. 3a, the cell viability analysis results in-
dicated that NOZ and SGC-996 cell proliferation levels
were significantly inhibited by PHB depletion in a time-
dependent manner. Interestingly, we found that the in-
hibitory effect of PHB depletion on cell proliferation was
more pronounced in NOZ cells than in SGC-996 cells.
Consistently, silencing PHB also markedly diminished
DNA synthesis in GBC cells, as reflected by the decreased
percentage of Edu-positive cells in PHB-knockdown NOZ
and SGC-996 cells (Fig. 3b and Additional file 1: Figure S1).
To better characterize the inhibitory effect induced by
PHB depletion in GBC cells, we performed cell cycle
analysis by flow cytometry. As shown in Fig. 3c, signifi-
cant increases in the proportion of cells in the G0/G1
phase were observed in PHB-knockdown NOZ and
SGC-996 cells compared with the negative control cells,
and accordingly, the fractions of cells in the S and G2/M
phases significantly decreased. In addition, we sought to
clarify whether the inhibitory effect of PHB depletion on
GBC cell growth partially resulted from the induction of
apoptosis. As shown in Additional file 2: Figure S2, there
were no significant changes in apoptosis detected in
PHB-knockdown NOZ and SGC-996 cells compared
with the negative controls. Taken together, these findings
demonstrate that PHB plays a crucial role in mediating
the proliferative capacities of GBC cells.
PHB inhibition reduced cell migration, invasion and active
MMP-9 secretion in GBC cells
Because the acquisition of an invasive phenotype by can-
cer cells has been regarded as a critical step in malignant
progression, we examined the effects of PHB depletion
on GBC cell migration and invasion. Both wound-healing
and transwell migration assays demonstrated that PHB de-
pletion substantially attenuated the migratory capabilities
Fig. 1 PHB overexpression was associated with a worse prognosis in GBC patients. a Representative photomicrographs of immunohistochemical
staining for PHB protein in chronic cholecystitis (Iand II) and GBC (III and IV) paraffin-embedded tissues. b Quantitative evaluation of PHB expression in
chronic cholecystitis and GBC tissue samples based on the staining intensity and percentage of stained cells. c Kaplan-Meier curves for the overall
survival in GBC patients with PHB-positive or negative expression. d Multivariate Cox regression analysis for the overall survival in GBC patients
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of NOZ and SGC-996 cells (Fig. 4a and b). Similarly, we
observed a remarkable reduction in the invasive potential
of the PHB-knockdown GBC cells compared with the re-
spective controls (Fig. 4c). Of note, we again found a more
potent inhibitory effect of PHB depletion on cell migration
and invasion in NOZ cells than in SGC-996 cells. Given
the essential role of MMPs in the invasive migration of
cancer cells, we evaluated the effect of PHB depletion on
active MMP synthesis and secretion using western blotting
and gelatin zymography assays. As shown in Fig. 4d and e,
downregulation of PHB expression dramatically sup-
pressed MMP-9 synthesis and active MMP-9 secretion in
NOZ and SGC-996 cells. Collectively, these observations
indicate that PHB is critically involved in the regulation of
GBC cell invasion.
Silencing of PHB suppressed GBC cell growth and
metastasis in vivo
To further substantiate the proposed role of PHB in the
promotion of GBC progression in vitro, we established
subcutaneous xenograft, peritoneal invasion and tail vein-
lung metastasis tumor models in BAL B/C nude mice with
NOZ cells. As shown in Fig. 5a, tumor growth was signifi-
cantly inhibited by PHB depletion compared with that in
the control group, as supported by the decreased vol-
ume of subcutaneous xenografts. Similarly, silencing of
PHB expression also markedly attenuated the metastatic
potential of GBC cells, as evidenced by the decreased peri-
toneal invasion and lung metastasis occurrence in the
PHB-depleted group compared to the controls (Fig. 5b
and c). Subsequently, we characterized PHB, p-ERK,
PCNA and MMP-9 expression levels in harvested subcuta-
neous xenografts by IHC staining. As shown in Fig. 5d, the
proliferative index PCNA and the invasive index MMP-9
were both markedly decreased; this effect was accompan-
ied by downregulated p-ERK expression in the PHB-
knockdown GBC tumors. Additionally, PHB depletion
resulted in a significant increase in the apoptotic index in
the NOZ cells’ subcutaneous xenografts, indicating that
PHB might be involved in GBC cell survival (Fig. 5e).
Taken together, these findings suggest that PHB depletion
inhibited GBC cell proliferation and metastasis in vivo.
Discussion
Recent work has reported that PHB is overexpressed in
several tumor types and plays crucial roles in cancer de-
velopment and progression [19–21]. Interestingly, our
microarray analysis of differential gene expression has
also demonstrated that PHB expression is considerably
upregulated in GBCs compared with that in their adja-
cent normal gallbladder tissues. In the present study, we
investigated PHB protein expression and its biological
functions in GBCs. We found that PHB protein was
overexpressed in the plasma membrane and cytoplasm
of GBC cells and was significantly associated with his-
tological grade, tumor stage and perineural invasion.
Furthermore, PHB overexpression was associated with
worse survival in GBC patients. In vitro experiments in-
dicated that downregulation of PHB expression dramat-
ically reduced cell proliferation and invasion in human
GBC cell lines (NOZ and SGC-996). Subsequently, we
explored the potential mechanism underlying the PHB-
mediated aggressive behavior in GBCs. We observed
that PHB expression in NOZ cells carrying the K-ras
mutation was much higher than that in SGC-996 cells
(K-ras wild-type). Moreover, PHB expression was con-
cordantly associated with p-ERK basal levels in NOZ
and SGC-996 cells. Furthermore, silencing of PHB expres-
sion contributed to a dramatic reduction in the activation
of ERK protein kinase, as reflected by the decreased
p-ERK expression. Additionally, PD0325901, a specific
inhibitor of MEK, markedly impaired PHB- mediated
phosphorylation of ERK protein. In human GBC tissue
samples, we identified a positive association between PHB
expression and the phosphorylation levels of ERK protein.
In vivo, PHB depletion not only inhibited the growth and
metastasis of GBC cells but also reduced the p-ERK ex-
pression level. Collectively, these findings suggest that
PHB overexpression might promote cell proliferation and
invasion through activating the ERK pathway, which plays
a crucial role in GBC progression.
Table 1 Relationship of PHB expression and clinicopathological
characteristics of GBC
Variable NO. of cases PHB-positive N (%) P value
Age
<60 18 12 (66.7)
≥60 56 45 (80.4) 0.379
Gender
Male 21 14 (66.7)
Female 53 43 (81.1) 0.304
Histological grade
Well 17 9 (52.9)
Moderately 33 26 (78.8)
Poorly 24 22 (91.7) 0.014
Pathologic T stage
Tis-T1 15 7 (46.7)
T2-T4 59 50 (84.7) 0.005
Nodal metastasis
Absent 31 21 (67.7)
Present 43 36 (83.7) 0.107
Perineural invasion
Absent 35 23 (65.7)
Present 39 34 (87.2) 0.028
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As an evolutionarily conserved and ubiquitously ex-
pressed protein, PHB contains an N-terminal transmem-
brane domain, an evolutionarily conserved PHB domain
that is similar to that of lipid raft associated proteins,
and a C-terminal coiled-coil domain that is involved in
the regulation of protein-protein interactions [22–24].
Recent studies in human cervical and pancreatic cancers
have demonstrated that the direct interaction of PHB
with C-Raf is required for the localization and phosphor-
ylation of C-Raf at serine 338 at the plasma membrane
and results in the RAS-mediated activation of Raf and
the downstream activation of the ERK pathway [13, 14, 25].
Here, we observed that PHB protein was primarily local-
ized to the plasma membrane and cytoplasm in human
GBC tissues and cultured GBC cell lines (NOZ and SGC-
996). Intriguingly, the PHB expression level in NOZ cells
carrying the K-ras mutation was much higher than that in
SGC-996 cells (K-ras wild-type). Furthermore, PHB ex-
pression was concordantly associated with the proportion
of p-ERK among total ERK protein. Upon depletion of
PHB in GBC cells, we observed a dramatic reduction in
the ERK pathway activation, as reflected by the decreased
p-ERK levels. The statistical analysis of the IHC staining
results validated that PHB overexpression was frequently
accompanied by the upregulation of p-ERK expression in
GBC tissue specimens. Based on these observations, we
postulated that the localization of PHB within the plasma
membrane might be critically involved in ERK pathway
modulation in GBCs. More recently, rocaglamide, a nat-
ural anticancer compound derived from the traditional
Chinese medicinal plant Aglaia, has been shown to select-
ively bind to PHB protein with nanomolar affinity in
Fig. 2 The regulatory effect of PHB on ERK pathway activation in GBCs. a PHB protein expression and distribution in NOZ and SGC-996 cells were
detected by immunofluorescence staining. b PHB, p-ERK and ERK expression levels in NOZ and SGC-996 cells were quantified by western blotting
analysis. β-actin was used as the loading control. c PHB overexpression was frequently accompanied by upregulation of p-ERK expression in GBC
tissue specimens. d PHB, p-ERK and ERK expression levels in Lv-sh NC and Lv-sh PHB GBC cells were determined by western blotting. e and f The
NOZ and SGC996 cells overexpressing PHB were treated with PD0325901 (20 nmol) or vehicle for 24 h followed by the analyses of western blotting
and gelatin zymography assays
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human cervical cancer cell line HeLa and human T cell
leukemic cell line Jurkat. In turn, this binding disrupts the
C-Raf-PHB interaction at the plasma membrane, thus
leading to the inactivation of the oncogenic Raf-MEK-
ERK signaling pathway [26]. Whether rocaglamide ex-
hibits similar anticancer effects in GBCs, especially the
ones harboring RAS mutations, needs to be further ex-
plored. It is also worth noting that the inhibitory effects of
PHB depletion on cell proliferation and invasion were
more pronounced in NOZ cells that harbored the K-ras
mutation than in SGC-996 cells (K-ras wild-type). This
observation implies that prospective selection of patients
with tumors carrying genetic alterations in the ERK path-
way is likely to identify a subgroup of individuals who may
benefit from the C-Raf -PHB interaction-targeted therapy.
Although PHB expression has been demonstrated to
be considerably upregulated in several types of human
cancers, the role of PHB in tumorigenesis remains con-
troversial. PHB protein was initially found in the mito-
chondrial inner membrane and plays a central role in
maintaining mitochondrial morphology and normal func-
tions, thus preventing apoptosis in malignant cells against
metabolic stress [27–29]. Recently, PHB has been revealed
to be indispensable for Raf-MEK-ERK pathway activation
by the oncogene Ras, supporting the pro-tumorigenic role
of PHB in cancer progression [14, 30, 31]. Nevertheless,
accumulating evidence has also highlighted the anti-
tumorigenic properties of PHB localized within the nu-
cleus. Through the interaction with the retinoblastoma in
the nucleus, PHB could suppress E2F-mediated transcrip-
tion for cell cycle progression, thereby resulting in the in-
hibition of malignant cellular growth [32, 33]. In this
study, we found that PHB protein was primarily localized
to the plasma membrane and cytoplasm in GBC cells.
Fig. 3 Silencing of PHB expression inhibited GBC cell proliferation in vitro. a The viability of NOZ and SGC-996 cells at the indicated time points
after transfection was evaluated using a CCK-8 cell viability assay. b DNA synthesis in Lv-sh NC and Lv-sh PHB GBC cells was examined using the
Edu incorporation assay. Representative fluorescence images are shown. c Cell cycle distribution in Lv-sh NC and Lv-sh PHB GBC cells was
analyzed by flow cytometry. Representative fluorescence histograms and the percentage of cells in each phase are shown. (*p < 0.05 compared
with the Lv-sh NC group)
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Furthermore, PHB overexpression was associated with
poor outcome in GBC patients. More importantly, silen-
cing of PHB expression potently suppressed GBC cell
proliferation and invasion in vivo and in vitro. These ob-
servations indicated that PHB may be pro-tumorigenic
rather than a tumor suppressor in GBCs. Based on
these findings, we speculated that the paradoxical anti-
tumorigenic or pro-tumorigenic effect of PHB on different
cell types might be determined by protein-protein interac-
tions in different subcellular localizations. Moreover, we
also observed that PHB depletion induced a significant
increase in apoptosis in the NOZ cells’ subcutaneous
xenografts. Given the previously reported function of
mitochondrial PHB in enhancing cellular survival against
metabolic stress, we postulated that PHB protein expressed
in the cytoplasm of GBC cells might be at least partially re-
stricted to the mitochondria and that silencing of the mito-
chondrial PHB weakened the capacity of GBC cells to
survive in an intratumoral malnutrition microenvironment
induced by the rapid proliferation of malignant cells.
Conclusions
In summary, we demonstrated that PHB overexpression
was associated with an unfavorable prognosis in GBC
patients. Furthermore, downregulation of PHB expres-
sion reduced proliferation and invasion in GBC cells via
the ERK pathway. Therefore, PHB may be a potential
prognostic and therapeutic biomarker in GBC patients.
Fig. 4 Downregulation of PHB expression diminished the migration and invasion of GBC cells in vitro. a The migration capacities of Lv-sh NC and
Lv-sh PHB GBC cells were assessed using a wound-healing migration assay. At 0 and 24 h after wounding, representative phase-contrast
photomicrographs and wound closure rates are shown. b The inhibitory effect of PHB depletion on GBC cell migration was further substantiated
using a transwell migration assay. Representative migrated cell-stained images and the number of migrated cells are shown. c The invasive potentials
of Lv-sh NC and Lv-sh PHB GBC cells were evaluated using a transwell invasion chamber assay. Representative invaded cell-stained images and the
numbers of invaded cells are shown. d A gelatin zymography assay was conducted to detect active MMP secretion in Lv-sh NC and Lv-sh PHB GBC
cells. Representative gelatin images and densitometry values of active MMP bands are shown. e The effect of PHB depletion on MMP-9 synthesis in
GBC cells was determined by western blotting analysis. (*p < 0.05 compared with the Lv-sh NC group)
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The use of animals and the experimental protocol
were approved by the Institutional Animal Care and Use
Committee of Xinhua Hospital, School of Medicine,
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formed in accordance with relevant guidelines and regu-





Additional file 1: Figure S1. The effects of PHB knockdown on DNA
synthesis in NOZ and SGC-996 cells were evaluated using the Edu
incorporation assay. The percentages of Edu-positive GBC cells in the
Lv-sh NC and Lv-sh PHB groups are shown. (*p < 0.05 compared with the
Lv-sh NC group). (TIF 62 kb)
Additional file 2: Figure S2. Apoptosis changes in Lv-sh NC and Lv-sh
PHB GBC cells were analyzed by flow cytometry. Representative fluorescence
scatter diagrams and the percentages of cells in survival, early apoptosis and
late apoptosis are shown. (*p < 0.05 compared with the Lv-sh NC group).
(TIF 135 kb)
Abbreviations
AJCC: American Joint Committee on Cancer; CCK-8: cell counting kit-8;
DAPI: 4’,6-diamidino-2-phenylindole; ERK: extracellular signal-regulated kinase;
GBC: gallbladder cancer; IHC: immunohistochemistry; MMP: matrix
metalloproteinase; PCNA: proliferating cell nuclear antigen; PHB: prohibitin;
Fig. 5 Downregulation of PHB expression induced a dramatic reduction in the growth and metastasis of GBC cells in vivo. a Subcutaneously
established NOZ cell-derived tumors in nude mice were monitored every 4 days until the mice were sacrificed on the 28th day. The harvested
xenografts and tumor growth curves are presented. b and c The peritoneal invasion and tail vein-lung metastasis tumor models were employed
to confirm the pro-metastatic role of PHB in GBCs. The peritoneal invasion and lung metastasis occurrence are shown, respectively. d PHB, p-ERK,
PCNA and MMP-9 expression levels in harvested tumor tissues were determined using an IHC staining assay. e The extent of cell apoptosis in the
tumor specimens was detected using a TUNEL apoptosis assay. Representative fluorescence images and the mean percentages of apoptosis cells
are shown. (*p < 0.05 compared with the Lv-sh NC group)
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PI: propidium iodide; shRNA: short hairpin RNA; TUNEL: terminal
deoxynucleotidyl transferase dUTP nick-end labeling.
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